Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth.
Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million
- Details
- Category: Merck Group
Merck Group third-quarter total revenues increased 25% to a record EUR 2,438 million from EUR 1,950 million in the year-ago quarter, boosted by the EUR 5.1 billion acquisition of Millipore Corporation, Billerica, Massachusetts, USA, on July 14.
AstraZeneca initiates phase IIB study for AZD9773
- Details
- Category: AstraZeneca
AstraZeneca has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. The Phase IIb study is a multicentre, randomised, double-blind, placebo controlled trial in 300 patients which will evaluate the efficacy of two intravenous dosing regimens of AZD9773.
FDA approves Herceptin for HER2-positive metastatic stomach cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.
Novartis delivers excellent performance in third quarter
- Details
- Category: Novartis
Net sales rose 13% (+16% cc) to USD 12.6 billion with strong contributions from all businesses. Currency movements depressed the result by 3 percentage points. Rapid growth of recently launched products across the Group generated USD 2.3 billion in sales, representing 20%* of total sales.
US FDA Approves Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate),(1) Boehringer Ingelheim's novel, oral direct thrombin inhibitor(2) for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.
More Pharma News ...
- Genzyme Reports Financial Results for the Third Quarter of 2010
- Genzyme Announces Results of Phase 3 Trial of Clolar
- Sanofi-aventis Establishes Research Collaboration with Harvard University
- Biocon and Pfizer Enter Into Global Commercialization Agreement
- Roche Group posts solid sales growth in first nine months
- GSK outlines approach to delivering advances in the treatment of rare diseases
- Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis